Remove Drugs Remove Immune Response Remove In-Vitro Remove In-Vivo
article thumbnail

CohBar and Morphogenesis in merger for immuno-oncology therapies

Pharmaceutical Technology

Morphogenesis’s technologies include Immune Fx (IFx) personalised cancer vaccines and tumour microenvironment (TME) modulators. IFx has been designed to activate an innate immune response against tumour antigens that are patient-specific. Morphogenesis’ lead personalised cancer vaccine, IFx-Hu2.0,

article thumbnail

Evusheld long-acting antibody combination approved in the EU for pre-exposure prophylaxis (prevention) of COVID-19 in a broad population

The Pharma Data

There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1, 6,7 This study also showed Evusheld reduced viral burden and limited inflammation in the lungs (in vivo) across all Omicron variants.6. Christoph D.

article thumbnail

AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development

The Pharma Data

Xiaomin Fan, Founder, President and CEO of AvantGen, “Even with the recent Emergency Use Authorization of multiple vaccines, we believe there remains an urgent need for potent antibody therapies and prophylactics for immunocompromised patients who cannot mount an adequate immune response either to the vaccine or to subsequent viral infection.